Diagnosis and treatment of cerebrogeloma
A cerebrogeloma is the most common primary tumor in the central nervous system. Its complex biological characteristics and diversity of clinical performance make it a major challenge in the field of neurotumours. The treatment of cerebrogeloma requires the development of individualized treatments that take into account the type, location, age and health of the patient. Detailed information on the definition, classification, causes, symptoms, diagnosis and main treatments for cerebrogeloma will be provided. (a) Definition and classification Rubber cells are widely distributed in the nervous system to support and nourish neurons. When the mutation of the glycol cells is out of control, they accumulate in an disorderly manner to form a cerebrogel tumor. On the basis of the cytological origin and histological characteristics of the tumour, the following types can be classified: 2. Tetraglytic tumours: originating in less glycol cells, which are usually rare and can be graded with degree of malignity. 3. Momentum of the room: Momentum cells originating in the brain, commonly found in children. 4. Mixed glycolomas: They contain different types of glycol cell composition, with different degrees of malignity and prognosis depending on the proportion of the ingredient. The World Health Organization (WHO) graded the cytological and tissue properties of the tumours, with the higher the level from I to IV, the faster the growth, the higher the degree of malignity, the lower the prognosis. The cause of the disease is not yet entirely clear, but has been found to be related to a number of factors. Genetic factors are one of the factors in which the absence and mutation of certain genes, as well as family history, may increase the risk of cerebrogeloma. In addition, environmental factors such as long-term exposure to electromagnetic radiation, air pollution, chemical substances, etc., can induce cerebro-geloma. Traumas, hormones, immune factors, physical factors, chemical factors and biological factors may also be associated with the onset of cerebrogelomas. Symptoms vary according to the location, size and growth rate of the tumor. Common symptoms include: 1. Headaches: often initial symptoms, which may increase over time. Epilepsy: particularly in the case of adults with no history of epilepsy, there should be a high level of suspicion of geloma. 3. Symptoms of the nervous system: muscular incompetence, sensory disorders, speech disorders, etc., depending on the brain area with tumours. 4. Cognitive change: reduced memory, low focus, etc. 1. Visual screening: MRI: is the most important means of screening, providing detailed images of tumours and helping to assess their size, location and impact on the surrounding tissue. CT: Assistive diagnostics may also be used in certain cases. 2. Organization of pathological examinations: A pathological analysis of tissues obtained through surgical removal or needle-suction work to determine the type and classification of tumors. 1. Surgery is the basis for the treatment of cerebrogeloma, with the aim of as complete a tumour as possible, while preserving normal brain tissue and nervous functions. The procedure consists of tumour ectomy and biopsy. The surgical risks include haemorrhage, infection and post-operative neurological impairment, which needs to be fully assessed prior to the operation. The biopsy is performed in cases where it cannot be fully removed to determine the type, level and degree of malignity of the glucoma. 2. Rehabilitation is usually performed after surgery, especially for high-level gelatinomas, to eliminate residual cancer cells and reduce the risk of relapse. It can also be used for patients who do not meet the conditions of surgery. The program can be: – Externally: Using high-energy radiation target to the tumor area. To kill or inhibit the growth of tumor cells. – Stereo-directed radiotherapy: accurate radiation of tumours and reduction of damage to normal surrounding tissue. 3. Chemotherapy is an important component of the comprehensive treatment of cerebrogeloma, and chemotherapy drugs can play a toxic role through blood and brain barriers. For high-level gelatinoma, there is usually a need for joint medicine. For example, the joint treatment of gel mother-cell tumours for methamine. Other drugs include sulphate sulphate sulphate, Lomostin capsules, propchapa tablets, etc. The side effects of chemotherapy, including nausea, vomiting, fatigue and haematological changes, require close monitoring. Immunotherapy provides new hope for treatment for people with cerebrogeloma. Immunosuppressants enhance the identification and attack of tumour cells in the immune system and reduce the release of chemotherapy responses. The development of an individualized vaccine for specific antigens for vaccine treatment is also under study and, although it is still at the experimental stage, has opened up new possibilities for treatment for gelatinoma patients. The treatment is complex and challenging. With the depth of research and the development of new technologies, our understanding of cerebrogeloma is growing, and there are bright prospects for future treatment. It is hoped that more patients will benefit and lead a better life.
